Aptevo Therapeutics Inc. (APVO)
| Bid | 1.77 |
| Market Cap | 2.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -87.38 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | -0.31 |
| Analyst | Buy |
| Ask | 1.84 |
| Volume | 75,882,909 |
| Avg. Volume (20D) | 497,421 |
| Open | 1.48 |
| Previous Close | 1.38 |
| Day's Range | 1.48 - 2.64 |
| 52-Week Range | 0.94 - 180.19 |
| Beta | 5.75 |
About APVO
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational ...
Analyst Forecast
According to 1 analyst ratings, the average rating for APVO stock is "Buy." The 12-month stock price forecast is $296, which is an increase of 14549.11% from the latest price.
Stock Forecasts
1 month ago · accessnewswire.com
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% ...
